Annual Cash & Cash Equivalents
$9.25 M
-$27.72 M-74.97%
31 December 2023
Summary:
Aptose Biosciences annual cash & cash equivalents is currently $9.25 million, with the most recent change of -$27.72 million (-74.97%) on 31 December 2023. During the last 3 years, it has fallen by -$108.14 million (-92.12%). APTO annual cash & cash equivalents is now -92.12% below its all-time high of $117.39 million, reached on 31 December 2020.APTO Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
N/A
30 September 2024
Summary:
Aptose Biosciences quarterly cash and cash equivalents is not available.APTO Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
APTO Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -75.0% | - |
| 3 y3 years | -92.1% | - |
| 5 y5 years | -39.5% | - |
APTO Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -92.1% | at low | ||
| 5 y | 5 years | -92.1% | at low | ||
| alltime | all time | -92.1% | +2879.7% |
Aptose Biosciences Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| June 2024 | - | $8.33 M(+13.4%) |
| Mar 2024 | - | $7.35 M(-20.6%) |
| Dec 2023 | $9.25 M(-75.0%) | $9.25 M(-41.1%) |
| Sept 2023 | - | $15.72 M(+87.1%) |
| June 2023 | - | $8.40 M(-63.1%) |
| Mar 2023 | - | $22.76 M(-38.4%) |
| Dec 2022 | $36.97 M(-5.5%) | $36.97 M(+32.1%) |
| Sept 2022 | - | $27.99 M(-30.1%) |
| June 2022 | - | $40.03 M(+8.2%) |
| Mar 2022 | - | $36.99 M(-5.4%) |
| Dec 2021 | $39.11 M(-66.7%) | $39.11 M(-47.9%) |
| Sept 2021 | - | $75.09 M(-9.9%) |
| June 2021 | - | $83.34 M(-4.3%) |
| Mar 2021 | - | $87.08 M(-25.8%) |
| Dec 2020 | $117.39 M(+47.0%) | $117.39 M(+17.7%) |
| Sept 2020 | - | $99.73 M(+84.3%) |
| June 2020 | - | $54.11 M(-9.4%) |
| Mar 2020 | - | $59.75 M(-25.2%) |
| Dec 2019 | $79.84 M(+421.9%) | $79.84 M(+286.0%) |
| Sept 2019 | - | $20.69 M(-23.1%) |
| June 2019 | - | $26.90 M(+62.2%) |
| Mar 2019 | - | $16.58 M(+8.4%) |
| Dec 2018 | $15.30 M(+43.9%) | $15.30 M(+1.6%) |
| Sept 2018 | - | $15.06 M(-16.1%) |
| June 2018 | - | $17.94 M(+16.5%) |
| Mar 2018 | - | $15.41 M(+44.9%) |
| Dec 2017 | $10.63 M(+33.9%) | $10.63 M(+33.8%) |
| Sept 2017 | - | $7.95 M(+0.4%) |
| June 2017 | - | $7.92 M(-11.7%) |
| Mar 2017 | - | $8.97 M(+12.9%) |
| Dec 2016 | $7.94 M(-4.5%) | $7.94 M(+1.0%) |
| Sept 2016 | - | $7.86 M(-19.2%) |
| June 2016 | - | $9.73 M(+87.4%) |
| Mar 2016 | - | $5.19 M(-37.5%) |
| Dec 2015 | $8.31 M(-32.8%) | $8.31 M(-26.3%) |
| Sept 2015 | - | $11.28 M(-17.8%) |
| June 2015 | - | $13.73 M(+37.9%) |
| Mar 2015 | - | $9.96 M(-34.4%) |
| Dec 2014 | $12.37 M(-30.7%) | - |
| Sept 2014 | - | $15.18 M(-14.9%) |
| May 2014 | $17.85 M(+2717.0%) | $17.85 M(+174.7%) |
| Feb 2014 | - | $6.50 M(+296.9%) |
| Nov 2013 | - | $1.64 M(+188.1%) |
| Aug 2013 | - | $568.20 K(-10.3%) |
| May 2013 | $633.60 K(+104.1%) | $633.60 K(-58.2%) |
| Feb 2013 | - | $1.52 M(-46.5%) |
| Nov 2012 | - | $2.83 M(-32.0%) |
| Aug 2012 | - | $4.17 M(+1243.3%) |
| May 2012 | $310.50 K(-66.7%) | $310.50 K(+199.7%) |
| Feb 2012 | - | $103.60 K(-87.4%) |
| Nov 2011 | - | $819.30 K(-52.9%) |
| Aug 2011 | - | $1.74 M(+86.5%) |
| May 2011 | $932.60 K | $932.60 K(-50.6%) |
| Feb 2011 | - | $1.89 M(+2.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Nov 2010 | - | $1.84 M(+761.3%) |
| Aug 2010 | - | $214.10 K(-66.1%) |
| May 2010 | $632.20 K(-87.2%) | $632.20 K(-25.2%) |
| Feb 2010 | - | $844.80 K(-63.5%) |
| Nov 2009 | - | $2.32 M(+192.9%) |
| Aug 2009 | - | $790.70 K(-84.0%) |
| May 2009 | $4.93 M(+84.8%) | $4.93 M(+10.9%) |
| Feb 2009 | - | $4.45 M(-8.4%) |
| Nov 2008 | - | $4.86 M(-28.4%) |
| Aug 2008 | - | $6.78 M(+154.2%) |
| May 2008 | $2.67 M(+103.1%) | $2.67 M(-23.1%) |
| Feb 2008 | - | $3.47 M(-29.7%) |
| Nov 2007 | - | $4.94 M(+54.2%) |
| Aug 2007 | - | $3.20 M(+143.8%) |
| May 2007 | $1.31 M(-46.3%) | $1.31 M(-32.7%) |
| Feb 2007 | - | $1.95 M(-68.4%) |
| Nov 2006 | - | $6.17 M(-48.7%) |
| Aug 2006 | - | $12.02 M(+391.6%) |
| May 2006 | $2.45 M(+10.5%) | $2.45 M(-66.0%) |
| Feb 2006 | - | $7.20 M(-20.1%) |
| Nov 2005 | - | $9.01 M(+74.7%) |
| Aug 2005 | - | $5.16 M(+133.1%) |
| May 2005 | $2.21 M(+181.3%) | $2.21 M(+48.1%) |
| Feb 2005 | - | $1.49 M(-67.5%) |
| Nov 2004 | - | $4.60 M(-17.3%) |
| Aug 2004 | - | $5.56 M(+606.9%) |
| May 2004 | $786.50 K(+19.2%) | $786.50 K(-51.5%) |
| Feb 2004 | - | $1.62 M(-32.0%) |
| Nov 2003 | - | $2.38 M(-83.4%) |
| Aug 2003 | - | $14.35 M(+2075.7%) |
| May 2003 | $659.60 K(-13.5%) | $659.60 K(-69.2%) |
| Feb 2003 | - | $2.14 M(-4.6%) |
| Nov 2002 | - | $2.25 M(+88.4%) |
| Aug 2002 | - | $1.19 M(+56.4%) |
| May 2002 | $762.50 K(-57.9%) | $762.50 K(-73.0%) |
| Feb 2002 | - | $2.82 M(+148.2%) |
| Nov 2001 | - | $1.14 M(-75.3%) |
| Aug 2001 | - | $4.59 M(+153.9%) |
| May 2001 | $1.81 M(-94.7%) | $1.81 M(-82.1%) |
| Feb 2001 | - | $10.09 M(+462.2%) |
| Nov 2000 | - | $1.79 M(-85.0%) |
| Aug 2000 | - | $11.93 M(-64.9%) |
| May 2000 | $33.99 M(+3755.0%) | $33.99 M(+708.5%) |
| Feb 2000 | - | $4.20 M(+2995.6%) |
| Nov 1999 | - | $135.80 K(-71.0%) |
| Aug 1999 | - | $468.40 K(-46.9%) |
| May 1999 | $881.70 K(-1.2%) | $881.70 K(+166.0%) |
| Feb 1999 | - | $331.50 K(-27.3%) |
| Nov 1998 | - | $455.70 K(-52.0%) |
| Aug 1998 | - | $949.10 K(+6.3%) |
| May 1998 | $892.50 K(-31.7%) | $892.50 K(-44.8%) |
| Feb 1998 | - | $1.62 M(+43.7%) |
| Nov 1997 | - | $1.12 M(-42.2%) |
| Aug 1997 | - | $1.94 M |
| May 1997 | $1.31 M | - |
FAQ
- What is Aptose Biosciences annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Aptose Biosciences?
- What is Aptose Biosciences annual cash & cash equivalents year-on-year change?
- What is the all time high quarterly cash and cash equivalents for Aptose Biosciences?
What is Aptose Biosciences annual cash & cash equivalents?
The current annual cash & cash equivalents of APTO is $9.25 M
What is the all time high annual cash & cash equivalents for Aptose Biosciences?
Aptose Biosciences all-time high annual cash & cash equivalents is $117.39 M
What is Aptose Biosciences annual cash & cash equivalents year-on-year change?
Over the past year, APTO annual cash & cash equivalents has changed by -$27.72 M (-74.97%)
What is the all time high quarterly cash and cash equivalents for Aptose Biosciences?
Aptose Biosciences all-time high quarterly cash and cash equivalents is $117.39 M